---
title: "A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290976116.md"
description: "Helus Pharma™, a subsidiary of Cybin Inc. (NASDAQ: HELP) (Cboe CA: HELP), has announced that its APPROACH Phase 3 trial for HLP003, aimed at providing adjunctive treatment for major depressive disorder, has achieved over 86% enrollment. The company is progressing well towards meeting the requirements set by the FDA for the trial."
datetime: "2026-06-26T13:32:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290976116.md)
  - [en](https://longbridge.com/en/news/290976116.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290976116.md)
generator: "portal-rs"
---

# A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

Helus Pharma™, a subsidiary of Cybin Inc. (NASDAQ: HELP) (Cboe CA: HELP), has announced that its APPROACH Phase 3 trial for HLP003, aimed at providing adjunctive treatment for major depressive disorder, has achieved over 86% enrollment. The company is progressing well towards meeting the requirements set by the FDA for the trial.

### Related Stocks

- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)
- [CYBN.US](https://longbridge.com/en/quote/CYBN.US.md)

## Related News & Research

- [Cybin Executive Chair Eric H. L. So acquires 100,000 common shares worth $1.24 million](https://longbridge.com/en/news/298736201.md)
- [Eric H. L. So Discloses Investment at Cybin Inc. with 5.8% Stake](https://longbridge.com/en/news/298510248.md)
- [Weight Loss Trial Results Altering The Investment Case For Structure Therapeutics (GPCR)?](https://longbridge.com/en/news/298754574.md)
- [Cybin Chief Growth Officer Paul Glavine acquires 90,000 common shares for $1.04 million](https://longbridge.com/en/news/298476424.md)
- [Roche Holding (SWX:ROP) Gets Phase III Win And FDA Priority Review For Two Drugs](https://longbridge.com/en/news/298826245.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**